A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 22 May 2017 Planned End Date changed from 1 May 2018 to 26 Jul 2018.
- 22 May 2017 Planned primary completion date changed from 1 May 2018 to 26 Jul 2018.